Many neurodegenerative diseases are characterized by the formation of microscopically visible intracellular protein aggregates. a-Synuclein is the key aggregating protein in Parkinson's disease which is characterized by neuronal cytoplasmic Lewy body inclusions. Previous studies have shown relative sparing of neurons in Parkinson's disease and dementia with Lewy bodies that are positive for the vitamin D-dependent calcium-buffering protein, calbindin-D28k, and that a-synuclein aggregates are excluded from calbindin-D28k-positive neurons. Recent cell culture studies have shown that a-synuclein aggregation can be induced by raised intracellular-free Ca(II) and demonstrated that raised intracellular calcium and oxidative stress can act synergistically to promote a-synuclein aggregation. We hypothesized that calcipotriol, a potent vitamin D analogue used pharmaceutically, may be able to suppress calcium-dependent a-synuclein aggregation by inducing calbindin-D28k expression. Immunofluorescence and western blot analysis showed that calcipotriol potently induced calbindin-D28k in a dose-dependent manner in SH-SY5Y human neuroblastoma cells. Calcipotriol significantly decreased the frequency of a-synuclein aggregate positive cells subjected to treatments that cause raised intracellularfree Ca(II) (potassium depolarization, KCl/H 2 O 2 combined treatment, and rotenone) in a dose-dependent manner and increased viability. Suppression of calbindin-D28k expression in calcipotriol-treated cells using calbindin-D28k-specific siRNA showed significantly higher a-synuclein aggregation levels, indicating that calcipotriol-mediated blocking of calcium-dependent a-synuclein aggregation was dependent on the induction of calbindin-D28k expression. These data indicate that targeting raised intraneuronal-free Ca(II) in the brain by promoting the expression of calbindin-D28k at the transcriptional level using calcipotriol could prevent a-synuclein aggregate formation and ameliorate Parkinson's disease pathogenesis.
Parkinson's disease (PD) is one of the most common neurodegenerative movement disorders, with major symptoms of motor dysfunction, such as resting tremor, bradykinesia, rigidity, and postural instability (Gelb et al. 1999) . These symptoms are the consequence of the progressive loss of dopamine secreting neurons in the substantia nigra (Sn). As symptoms start to arise when 50-70% of neurons have been lost, diagnosis is only possible at an advanced stage of the disease (Sveinbjornsdottir 2016) . The main hallmark of PD is the presence of the neuronal cytoplasmic Lewy body inclusions in which the protein a-synuclein (a-syn) (14 kDa) is a key component (Cookson 2009; Jellinger 2009; Breydo et al. 2012; Marques and Outeiro 2012; Rcom-H'cheo-Gauthier et al. 2014) . To date, familial PD cases have been linked to six specific gene mutations in PARK1/4, the gene coding for asyn, with amino acid substitutions, A30P (Kruger et al. 1998) , A53T (Polymeropoulos et al. 1997) , E46K (Zarranz et al. 2004) , G51D (Lesage et al. 2013) , H50Q (Proukakis et al. 2013) , and A53E (Pasanen et al. 2014) . Misfolded a-syn is believed to be the driver of Lewy body formation in both familial and idiopathic cases, with many factors causing a-syn to misfold and aggregate, including oxidative stress, gene mutations and elevated concentrations of ions, such as Ca(II), Cu(II), or Fe(II) (Santner and Uversky, 2010; Rcom-H'cheoGauthier et al. 2016a) . Nielsen et al. (2001) reported that calcium binding to a low affinity EF-hand-like domain within the a-syn Cterminus caused aggregation and Lowe et al., (2004) subsequently showed that this binding promoted the formation of annular oligomers. Nath et al. (2011) confirmed that calcium accelerates a-syn oligomer formation in vitro and also showed that a transient increase in the intracellular-free Ca (II) concentration caused a significant increase in the proportion of cells bearing a-syn aggregates, which could be suppressed by intracellular Ca(II) chelator. More recently, Follett et al. (2013) , demonstrated that depolarization of the plasma membrane leading to an increase in intracellular-free Ca(II) by causing the opening of the voltage-gated calcium channels triggered a-syn aggregate formation in undifferentiated SH-SY5Y neuroblastoma cells, that could be blocked both by Ca(II) chelation and a calcium channel antagonist.
Early evidence for a role of calcium in PD pathogenesis was provided by Yamada et al. (1990) , who found that dopaminergic neurons of the Sn that were high in the vitamin D-dependent calcium-buffering protein Calbindin-D28k (CB) were preferentially spared in PD patients compared with controls, indicating that decreased Ca(II) buffering may be a major factor in the pathogenesis of a-synucleinopathies. Oligomeric a-syn has been shown to inhibit mitochondrial complex 1, induce mitochondrial depolarization and activate calcium signaling, triggering cell death via the intrinsic pathway (Angelova and Abramov 2017) . Influx of Ca(II) can also be mediated by oligomeric a-syn (Hettiarachchi et al. 2009 ). Furthermore, Ca(II) influx can interact with a-syn to mediate increased oxidative stress (Dryanovski et al. 2013; Surmeier et al., 2017) and the combination of raised intracellular-free Ca(II) and oxidative stress showed a synergistic effect on a-syn aggregation . Moreover, recent studies demonstrated that a-syn aggregates were almost completely excluded from CBpositive neurons in dementia with Lewy bodies and in a unilateral mouse model using lesion with the mitochondrial complex 1 inhibitor, rotenone (Rcom-H'cheo-Gauthier et al. 2016b) . Calcium has also been implicated recently in the mechanism of rotenone-mediated a-syn aggregation. Thus, intracellular calcium chelation has been found to attenuate rotenone-induced impairments of autophagy and rotenoneinduced a-syn aggregation was found to be mediated by the calcium/GSK3b signaling pathway (Yuan et al. 2015) .
Regulation of Ca(II) is vital for cell survival and function, and is tightly regulated via mitochondrial and endoplasmic reticulum stores and a number of proteins that are capable of Ca (II) buffering in neurons, such as CB, calretinin, and parvalbumin (Bu et al. 2003) . The importance of these proteins has been further implicated by German et al. (1992) who found both in idiopathic PD and in MPTP monkey or mouse models that neurons that were CB-positive were spared, whereas neurons in CB-negative regions were lost. Indeed, Yuan et al. (2013) found that mice over-expressing CB were protected from neuronal loss in a mouse oxidative stress PD model.
In this study, we show that SH-SY5Y neuroblastoma cells subjected to the vitamin D analogue, calcipotriol, show raised CB expression that is dose-dependent. We show that calcipotriol suppresses cytoplasmic a-syn aggregates promoted by raised Ca(II) by a CB-dependent mechanism, indicating that by promoting the expression of CB at the transcriptional level, calcipotriol targets raised neuronal intracellular-free Ca(II) and inhibits a-syn aggregation.
Materials and methods
Cell culture SH-SY5Y human neuroblastoma cells (ATCC â CRLÀ2266 TM ) were seeded at 20 000 cells/well in 24-well plates on 10 mm glass cover slips. Cells were incubated for a period of 24 h at 37°C with 5% CO 2 in 1 mL of 15% fetal bovine serum, 82.96% Dulbecco's modified Eagle's medium : F12 (Invitrogen, Carlsbad, CA, USA), 0.04% Amphotericin B and 1% Strep/Penicillin prior to drug treatment.
siRNA transfection
For siRNA transfection, cells were treated and seeded simultaneously at 20 000 cells/well on 10 mm glass cover slips. Cells were placed in 5 lL of transfection reagent (sc-29528; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 5 lL of CB siRNA (sc-29879) in 500 lL of transfection medium (sc-36868) for 7 h. Then, the medium was replaced and cells were incubated for 48 h. Transfection efficiency was measured using control siRNA-A (sc-37007) and control siRNA (FITC Conjugate)-A (sc-36869). Calcipotriol, K + , H 2 O 2 , and rotenone treatments SH-SY5Y cells were incubated in the presence of increasing concentrations of calcipotriol (0, 01, 0.5, 1, 5, or 10 nM) in serumfree Dulbecco's modified Eagle's medium for 5 h at 37°C with 5% CO 2 then washed twice with phosphate-buffered saline (PBS). The medium was then replaced with medium supplemented with 50 mM KCl for 1 h or 50 mM KCl and 10 lM H 2 O 2 for 1 h . For control cells, un-supplemented medium was used. Following treatment, cells were incubated with fresh medium for 36 h at 37°C with 5% CO 2 before fixing. For rotenone treatments, following calcipotriol treatment, cells were placed in 500 nM rotenone and incubated for 24 h at 37°C with 5% CO 2 before fixing. After incubation, post-treatment cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Immunohistochemistry/histology staining Cells were rinsed in PBS prior to fixation. Cells were fixed and permeabilized using 1 : 3 methanol : acetone and blocked with 20% normal horse serum. Monoclonal mouse anti-a-syn antibody (LB509; Invitrogen) and monoclonal rabbit anti-CB antibody (CB38; Swant, Marly, Switzerland) were used 1 : 100 for immunostaining. Alexa fluor-conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA, Invitrogen) were used for immunofluorescence and mounted using Prolong Gold with 4 0 ,6-Diamidino-2-Phenylindole (DAPI) mounting medium (Invitrogen). For thioflavin T staining, cells were first fixed in methanol: acetone then incubated for 8 min in freshly filtered 1% w/v thioflavin T (Sigma, St Louis, MO, USA) in ultrapure water. Then cells were rinsed with water, washed twice with PBS, differentiated with 1% ethanoic acid, rinsed twice in water then mounted. Microscope slides were stored in the dark at 4°C.
Confocal microscopy and image analysis
Immunostained coverslips were imaged using a Nikon A1R+ confocal laser microscope (Nikon, Tokyo, Japan). Negative control slides were imaged to set microscope settings (laser voltage, electronic gain, and offset) to appropriate levels. The 609 oil immersion lens was used for fixed cell imaging. DAPI, AF-488, and -568 were imaged together, on separate channels. Minimal nonspecific staining was observed without primary antibody. Immunostained cells were counted (n = 30) and classified as either a-syn inclusion body-positive or inclusion body-negative. A standardized pattern of 609 fields of view (n = 5) was imaged and counted using Columbus (PerkinElmer, Waltham, MA, USA) image analysis software. To be classified as a a-syn inclusion body-positive cell, clear and bright focal immunofluorescence needed to be observed in one or more confocal slice. The percentage of a-syn inclusion body positive cells was calculated along with inclusion body-negative cells. Experiments were then repeated with n = 5 for CB siRNA-treated cells. CB intensity was measured and low CB (siRNA transfected) or high CB (siRNA negative) cells in the siRNA transfection experiments were categorized using the CB immunofluorescence intensity levels in the cytoplasm.
Western blot analysis
Cells were rinsed in cold PBS prior to lysis in cold radioimmunoprecipitation assay (RIPA) buffer/protease inhibitor cocktail (Sigma). Adherent cells were scraped off the dish and maintained at constant agitation for 30 min at 4°C. Cells were centrifuged at 4°C for 5 min at 20 000 9 g; the supernatant was then stored at À20°C.
Each sample (20 lL) was run in triplicate on 8-16% Mini-PROTEAN â TGX Stain-Free TM Gels (Bio-Rad Laboratories, Hercules, CA, USA; 200 V, 30 min), transferred to nitrocellulose using Trans-Blot â Turbo TM Transfer System (Bio-Rad; 25 V, 30 min), blocked (1 h, 5% skimmed milk powder), incubated with primary rabbit anti-CB (Swant) antibody (1 : 1000, overnight) washed (39, Tris-buffered saline-Tween (TBS-T)), incubated with horseradish peroxidase-conjugated secondary antibody (1 : 2000, 1h; Bio-Rad washed (39, TBS-T)and developed with West Pico SuperSignal Chemiluminescent Substrate (ThermoFisher Scientific, Scoresby, Vic, Australia). Membranes were imaged by BioRad ChemiDoc TM MP System. For re-probing, blots were stripped with 0.2N NaOH for 30 min, then re-blocked and probed for actin (mouse anti-actin; Sigma). Bands were quantitated by area under the curve relative to actin loading controls (Image Lab TM software, Bio-Rad). Experiments were then repeated with n = 3.
Statistical analysis
All data were analyzed using SPSS Version 22.0. Standard error of the mean for graphs was calculated using r ffiffi n p . ANOVA tests were conducted to test for statistical significance.
Results
In this study, we were interested in probing the interaction between the calcium-buffering protein, CB, Ca(II), a-syn aggregates, and oxidative stress. We investigated whether calcipotriol treatment induces the expression of CB in SH-SY5Y human neuroblastoma cells and if this could inhibit calcium-dependent a-syn aggregation. We analyzed the expression of CB, and a-syn aggregation using established cell culture models after potassium depolarization, KCl/H 2 O 2 , and rotenone treatments, with and without calcipotriol pretreatment. We also treated the cells with CB-specific siRNA to knock down CB expression to observe the effect of calcipotriol on a-syn aggregation in the absence of CB induction.
Calcipotriol potently induces calbindin-D28k expression in SH-SY5Y cells SH-SY5Y cells were treated with calcipotriol at concentrations of 0, 0.1, 0.5, 1, 5, and 10 nM. After incubation for 5 h, cells retained normal morphology and MTT assay showed no significant difference in cell viability post-treatment at concentrations below 50 nM calcipotriol. With calcipotriol at 50 nM and above, MTT assay revealed a significant decrease in cell viability. Representative confocal immunofluorescence images are shown in Fig. 1 (a-c) from cells treated with calcipotriol 0-10 nM, showing that CB was expressed within the cytoplasm of SH-SY5Y cells. Figure 1 (a-c) shows the characteristic more intense uniform CB expression within cells treated with higher concentrations of calcipotriol.
To obtain a more quantitative view, immunofluorescence intensity of CB was measured for six concentrations of calcipotriol. The data summarized in Fig. 1 (e) shows significant differences in CB immunofluorescence intensity between the different concentrations of calcipotriol used. We observed an increase of 2-fold in the intensity of CB when treated with 10 nM calcipotriol (p < 0.0001) compared to control. We also observed an increase of 30% between the intensity of CB when treated with 10 nM calcipotriol compared to 1 nM calcipotriol (p < 0.0001).
To investigate the protein expression profile, western blot analysis was performed for CB. Western blots were subjected to integration of bands and were normalized to the band intensities of actin loading controls. Figure 1(d) shows representative CB western blots for different concentrations of calcipotriol treatment. Examination of the western blot data indicates the consistent presence of a major 28 kDa molecular weight band immunopositive for CB. The data summarized in Fig. 1 (e) shows significant differences in CB integral between the different concentrations of calcipotriol used. We observed an increase of 2.2-fold between the amount of CB when treated with 10 nM calcipotriol compared to control with a significance value of p < 0.0001. We also observed an increase of 1.4-fold between the CB integral when treated with 10 nM calcipotriol compared with 1 nM with a significance value of p < 0.0001. These findings correlate well with the measurements of CB expression using immunofluorescence. We did not observe statistically significant differences between the two methods of measurement after normalizing the results.
Calcipotriol pre-treatment suppresses the formation of asynuclein cytoplasmic aggregates SH-SY5Y cells were pre-treated with calcipotriol at concentrations of 0, 0.1, 0.5, 1, 5, and 10 nM to induce CB expression. Depolarization with 50 mM KCl, 50 mM KCl/ 10 lM H 2 O 2 combined treatment or 500 nM rotenone was employed to induce a-syn cytoplasmic aggregates. Previous studies have established that KCl depolarization results in a transient increase in free Ca(II) as measured by Calcium Crimson fluorescence, 90% of which could be suppressed by the T-type selective calcium channel blocker, trimethadione (TMO) (Follett et al. 2013) . Rotenone toxicity has also been attributed to calcium mobilization (Yuan et al. 2015) , whereas KCl/H 2 O 2 combined treatment yielded a synergistic effect on a-syn aggregation . Cells retained normal morphology, showing no signs of clumping or rounding by differential interference microscopy. To Fig. 2 (c) and (g) for 10 nM calcipotriol. We then treated cells with the mitochondrial complex I inhibitor, rotenone, which triggers both oxidative stress and increased intracellular-free Ca(II) (Yuan et al. 2015) . Few a-syn focal aggregates were observed by immunofluorescence analysis in the cells pre-treated with 1-10 nM calcipotriol compared to cells that did not receive pretreatment when a-syn aggregation was induced by rotenone as illustrated in Fig. 2 (k) for 10 nM calcipotriol. Thioflavin T fluorescence staining for amyloid-like filaments showed that KCl treatment yielded filamentous cytoplasmic inclusions and these were suppressed by calcipotriol pre-treatment to induce CB (Fig. 2q-x) .
To obtain a more quantitative view, a-syn aggregates were counted using Columbus (PerkinElmer) image analysis software for six concentrations of calcipotriol. Cells containing cytoplasmic a-syn aggregates were counted as a-syn aggregate-positive and the proportion of total cells was then calculated. The data summarized in Fig. 3(a) shows significant differences in a-syn aggregation between the different concentrations of calcipotriol used. Firstly, we observed a significant difference (p < 0.001) between the proportion of a-syn aggregate bearing cells when cells were treated with only KCl compared to KCl/H 2 O 2 combined treatment. There were 30% fewer a-syn aggregate positive cells with KCl treatment compared to treatment with a combination of KCl and H 2 O 2 . In addition, cells treated with KCl only showed fewer, larger aggregates in the cytoplasm, whereas cells treated with KCl/H 2 O 2 showed a greater multiplicity of aggregates of smaller size. These results were consistent with previous studies which examined the cooperative effect on a-syn aggregation of Ca(II) and oxidative stress . When cells were pre-treated with calcipotriol, we observed a progressive decrease in the frequency of a-syn aggregate positive cells with increasing calcipotriol concentration (Fig. 3a) . Cells that were treated with the combination of KCl/H 2 O 2 showed a significant (p < 0.0001) decrease in the proportion of asyn aggregate positive cells of 47% when pre-treated with 0.1 nM calcipotriol. When treated with a calcipotriol concentration of 0.5 nM, KCl-treated cells showed a significant (p < 0.001) decrease in the proportion of a-syn aggregate positive cells by 20%. There was no significant difference in the proportion a-syn aggregate positive cells at 0.1 nM calcipotriol with KCl treatment compared to control. Calcipotriol pre-treatment decreased significantly the proportion of a-syn aggregate positive cells with either KCl or KCl/H 2 O 2 treatments when the calcipotriol concentration was increased to 5 nM.
After cells were pre-treated with calcipotriol, we did not observe any significant difference in the proportion of a-syn aggregate positive cells between KCl or KCl/H 2 O 2 experiments at each calcipotriol concentration used. Cells treated with KCl/H 2 O 2 showed more a-syn aggregation than cells treated with KCl only, but when cells were pre-treated with calcipotriol, we observed similar aggregation in both groups.
When treated with rotenone only, we observed abundant a-syn aggregates. The a-syn aggregates observed were often single large (2 lm) inclusions in each cell, unlike the multiple smaller aggregates observed in the KCl/H 2 O 2 -treated cells. When treated with concentrations of calcipotriol from 0.1-10 nM, we observed a significant decrease in the proportion of a-syn aggregate positive cells. There was a significant (p < 0.001) decrease of 45% in a-syn aggregate positive cells when cells were treated with 1 nM calcipotriol compared to control.
Calcipotriol pre-treatment increases cell viability after KCl treatment To determine the effect of calcipotriol on cell viability after calcipotriol and KCl treatment, MTT viability assays were performed 4 days post-treatment. Figure 3(b) shows a 25% (p < 0.05) decrease in cell viability after KCl treatment compared to control. However, with 10 nM CB pre-treatment, we did not observe any statistical difference in cell viability between KCl treated and control groups. There were no significant differences in viability at earlier time points.
Cabindin-D28k siRNA blocks the inhibition of a-synuclein aggregation by calcipotriol To determine if calcipotriol-mediated suppression of calcium-dependent a-syn aggregation is because of increased CB expression, we employed CB-specific siRNA to inhibit CB expression in calcipotriol-treated cells. To examine CB expression in SH-SY5Y cells after siRNA and calcipotriol treatments, immunofluorescence confocal microscopy was performed on fixed cells. Representative images are shown in Fig. 4(a-c) from cells treated with 0-10 nM calcipotriol and siRNA. Figure 4(a-c) shows the characteristic more intense uniform CB expression within cells treated with higher concentrations of calcipotriol and lower CB expression in some cells because of the transfected siRNA.
To investigate the protein expression profile after siRNA and calcipotriol treatments, western blot analysis was performed for CB. Western blots were subjected to integration of bands and were normalized to the band intensities of actin loading controls. Figure 4(d) shows representative CB western blots for different concentrations of calcipotriol treatment. The data summarized in Fig. 4 (e) shows significant differences in CB intensity between the different concentrations of calcipotriol used. We observed a significant (p < 0.001) decrease of 50% between the cells treated with siRNA and untreated at 10 nM calcipotriol. This is consistent with the downregulation of CB by the CB siRNA as seen in the immunofluorescence data.
To delineate the effect of CB induction by calcipotriol on a-syn aggregation, cells were treated with CB-specific siRNA before calcipotriol and KCl treatments. Figure 5 (ai) shows the characteristic more intense uniform CB expression within cells treated with higher concentrations of calcipotriol and lower CB expression in cells transfected with siRNA. Figure 5(j-k) represents the output from the Columbus software determining a cell as siRNA+ or siRNAbased on mean immunofluorescence intensity of cells with red being cells that are below the CB expression threshold and green for cells above the threshold. The apparent rate of siRNA transfection determined by immunofluorescence analysis was 70%, which was consistent with the transfection efficiency determined with the siRNA control construct. In the siRNA transfected cells, we observed higher a-syn aggregation than in cells that were deemed not transfected, especially at 0.5 nM calcipotriol. Furthermore, when a-syn aggregates were present in cells over-expressing CB, their sizes were small and they were few in number. The data summarized in Fig. 6 (a) shows significant differences in a-syn aggregation between cells that were pre-treated with CB-siRNA compared to cells that were not subjected to siRNA treatment. We observed a significant decrease in a-syn aggregation p < 0.05 at 0, 0.1, and 0.5 nM calcipotriol, p < 0.01 at 5 nM and 10 nM calcipotriol and p < 0.001 at 1 nM calcipotriol. We still observed a 30% decrease (p < 0.0001) of a-syn aggregate positive cells between 1 and 5 nM calcipotriol in siRNA-treated cells, indicating that high calcipotriol concentration can compensate for the effect of the siRNA knock down. The data summarized in Fig. 6(b) shows significant differences in a-syn aggregation between cells deemed siRNA+ and siRNA-at all the concentrations of calcipotriol used for large (> 2 lm), small, and total aggregate bearing cells. We observed at all calcipotriol concentrations, a significant (p < 0.0001) increase of a-syn aggregation in cells that were judged to have taken up the CB-specific siRNA compared to cells that had not at each of the six different calcipotriol concentrations, with the proportionate decrease in aggregate bearing cells in siRNA-compared to siRNA+ being greater for small aggregates at lower calcipotriol concentrations. The cell counting data are summarized in Figure S1 . Discussion Yamada et al. (1990) first demonstrated the over-representation of neurons positive for the endogenous, vitamin D-dependent neuronal calcium-buffering protein, CB, in the Sn of PD patients. Subsequent studies using animal models have provided additional data to support a neuroprotective role for CB. Furthermore, a-syn aggregates have been found to be almost completely excluded from CB-positive neurons in an animal model and in dementia with Lewy bodies in humans (Rcom-H'cheo-Gauthier et al. 2016b). Moreover, cell culture models have established a causative link between raised intracellular-free calcium and a-syn aggregation (Nath et al. 2011; Follett et al. 2013) . Follett et al. (2013) prevented the formation of a-syn aggregates in cells after KCl treatment by pre-treating them with the 1,2-bis(o-aminophenoxy)ethane-N, N,N 0 ,N 0 -tetraacetic acid (BAPTA) intracellular calcium chelator. In this study, we sought to investigate a potential inhibitory effect of CB against a-syn aggregation in cell culture models of PD. We hypothesized that the vitamin D analogue, calcipotriol, may efficiently induce CB expression in a neuronlike cell line. We further hypothesized that increased CB expression could suppress the formation of cytoplasmic a-syn aggregates promoted by raised intracellular-free Ca(II) and oxidative stress.
SH-SY5Y human neuroblastoma cells were subjected to multiple treatments that trigger a-syn aggregation. Vitamin D and Vitamin D analogues have been shown to induce CB expression (Halhali et al. 2010 ), which we hypothesized, could reduce a-syn aggregation induced by potassium depolarization, combined KCl/H 2 O 2 treatment and rotenone treatment. We have shown that in the SH-SY5Y human neuroblastoma cell line, endogenous CB expression could be increased potently by low, non-toxic concentrations of calcipotriol (1 nM range). Calcipotriol pre-treatment also blocked the reduction in cell viability observed 4 days postKCl depolarization, correlating with the timescale of aggregate formation. We examined changes in CB levels and asyn protein aggregates between different calcipotriol concentration treatments. Immunofluorescence and western blotting showed that calcipotriol induced increased CB expression in a dose-dependent manner and this led to a reduction in a-syn aggregate bearing cells under each of the treatments used. This also correlated with reduced thioflavin T staining of amyloid-like inclusions in response to calcipotriol pre-treatment.
We hypothesized that the decrease in a-syn aggregation observed is directly linked to the increased CB expression. To test this hypothesis, we have pre-treated cells with CBspecific siRNA to prevent CB over-expression upon calcipotriol treatment. The results of the siRNA transfection experiments showed that cells that had taken up the CBspecific siRNA and consequently showed significantly lower levels of CB after calcipotriol treatment also showed significantly more a-syn aggregates than cells that showed the level of CB induction observed in the absence of siRNA. These results indicate that the reduced aggregation of a-syn observed upon calcipotriol treatment is due largely to the increase in CB expression and is likely a consequence of increased calcium buffering.
It is clear that free intracellular Ca(II) is a major factor influencing a-syn aggregation, and potentially the formation of the cytotoxic oligomeric species seen in PD. Lowe et al. showed that Ca(II) binding to the C-terminus of a-syn could induce annular oligomers (Lowe et al. 2004) . It was demonstrated that raised Ca(II) promotes a-syn aggregation both in vivo and in vitro (Nath et al. 2011; Follett et al. 2013) and that Ca(II) and oxidative stress can cooperatively induce a-syn aggregates in a cell culture model system ). More recently it was found that a-syn oligomers disrupt calcium regulation in cells and lead to calcium-dependent cell death (Angelova et al. 2016) . Moreover, recent findings suggest an association between raised intracellular Ca(II), a-syn aggregation, and neurotoxicity paving the way for the development of therapeutics that target raised Ca(II) (Schapira et al. 2014) . Targeting Ca(II) dysregulation, by using drugs that modulate the amount of intracellular-free Ca(II) provides a therapeutic target to treat PD. Calcium influx is tightly regulated by plasma membrane calcium channels, such as those from the voltage-gated Ca v 1, Ca v 2, and Ca v 3 classes that have been implicated in neurodegeneration (Rcom-H'cheo-Gauthier et al. 2016a). Ca(II) channel blockers, such as those from the dihydropyridines family, that target the calcium channels in neurons may be used to lessen the increase in intracellular Ca(II). However, this study suggests that induction of endogenous CB might also be effective at reducing Ca(II)-dependent neuronal a-syn aggregation and cytotoxicity.
Major metabolites of vitamin D have been found to be present in human cerebrospinal fluid, including 25OHD3 (Calcifediol), 1,25OH2D3 (Calcitriol), and 24,25OH2D3 (24,25-Dihydroxycholecalciferol) (Balabanova et al. 1984) . Furthermore, vitamin D metabolites have been shown to cross the blood-brain barrier (Pardridge et al. 1985) . CYP27B1 is present in both neurons and glia and is most strongly expressed in the Sn and the supraoptic and paraventricular nuclei of the hypothalamus in the adult brain (Eyles et al. 2005) . This potentially indicates that the brain may be able to synthesize the active metabolite 1,25OH2D3. CB over-expression in a transgenic mouse model was also able to protect neurons against MPTP toxicity (Yuan et al. 2013) . Since Ca(II) lowering medications, such as anti-epileptic drugs, often have significant side-effects, efficiently buffering raised intracellular-free Ca (II) in the brain by promoting the expression of CB at the transcriptional level by using calcipotriol may offer an effective alternative.
Previous research has found that administration of 1,25OH2D3 protects against damage from the neurotoxin, 6-hydroxydopamine, that specifically lesions dopaminergic and noradrenergic cells (Wang et al. 2001; Smith et al. 2006) . Furthermore, administration of 1,25OH2D3 has been shown to protect against neurotoxic doses of methamphetamine by preserving dopamine and serotonin levels . Such neuroprotection of dopaminergic neurons may be relevant to the loss of dopaminergic neurons in the Sn in PD. Thus, CB over-expression was found to protect against MPP+ neurotoxicity by inhibiting caspase and calpain activity and prevents 6-OHDA induced apoptosis by activating PI3-Akt signaling (Choi et al. 2008; Sun et al. 2011 ). In addition, some studies have linked vitamin D insufficiency with increased risk of PD (Newmark and Newmark 2007; Evatt et al. 2008) . Moreover, higher levels of 25OHD3 were associated with a reduced risk of developing PD in later life (Knekt et al. 2010) . Abnormalities in the vitamin D receptor have also been linked with risk of developing PD (Kim et al. 2005) . On the other hand, a recent study by Shrestha et al. (2016) has investigated the possible association between serum 25-hydroxyvitamin D concentration in mid-adulthood and PD risk, and found no association between vitamin D and the risk of PD. Our experimental results indicate that calcipotriol could be neuroprotective by reducing a-syn aggregate formation, however, further animal model studies would be required to determine if calcipotriol can induce increased CB expression in differentiated neurons in the brain tissue context.
Conclusion
This study demonstrates that CB can be effectively induced in neuron-like cells using the vitamin D analogue, calcipotriol, and that increased CB expression induced by calcipotriol treatment can directly suppress intracellular asyn aggregation caused by high levels of free Ca(II) and oxidative stress. Although additional work is necessary to delineate the effects of calcipotriol treatment in an animal model system, this study points toward CB induction as a novel therapeutic target in PD. All experiments were conducted in compliance with the ARRIVE guidelines.
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